FDA
-
-
-
-
-
-
-
Seaport Therapeutics doses first patient in GlyphAgo anxiety trial
-
-
-
-
-
-
-
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgoâ„¢ in Healthy Volunteers
333,673 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


